US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Array Digital Infrastructure Inc.

38.12

+0.07000.18%

Post-market: 38.120.00000.00%19:30 EDT

Volume:187.41K

Turnover:7.14M

Market Cap:3.29B

PE:6.16

High:38.36

Open:38.29

Low:37.75

Close:38.05

52wk High:60.82

52wk Low:33.71

Shares:86.38M

Float Shares:15.56M

Volume Ratio:0.72

T/O Rate:1.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):6.19

EPS(LYR):0.5551

ROE:22.68%

ROA:0.02%

PB:2.60

PE(LYR):68.68

Loading ...

Overview Company News Filings

Array Digital Infrastructure approves 2026 annual incentive plan with 80% company performance weighting

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

Apogee data for zumilokibart in AD ‘a home-run success,’ says Citi

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

AdAlta secures Canadian patent to complete global AD-214 protection

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Longeveron Announces 2025 Full Year Financial Results and Provides Business Update

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026

Maintaining Buy on Acumen (ABOS): EBD-Enabled Alzheimer’s Pipeline, Extended Runway, and Discounted Valuation Ahead of ALTITUDE-AD Readout

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/AD/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"AD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","market":"US","secType":"STK","nameCN":"Array Digital Infrastructure Inc.","latestPrice":38.12,"timestamp":1789156800000,"preClose":38.05,"halted":0,"volume":187406,"hourTrading":{"tag":"盘后","latestPrice":38.12,"preClose":38.12,"latestTime":"19:30 EDT","volume":1047,"amount":39911.64,"timestamp":1789169408128,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0018396846254927803,"floatShares":15563300,"shares":86379877,"eps":6.185934,"marketStatus":"Market Closed","change":0.07,"latestTime":"09-11 16:00:00 EDT","open":38.29,"high":38.36,"low":37.75,"amount":7144444.830108001,"amplitude":0.016032,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":6.185934,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NYSE","adjPreClose":38.05,"postHourTrading":{"tag":"盘后","latestPrice":38.12,"preClose":38.12,"latestTime":"19:30 EDT","volume":1047,"amount":39911.64,"timestamp":1789169408128,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7206132626798357,"impliedVol":0.3382,"impliedVolPercentile":0.592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AD\",,,,,undefined,":{"symbol":"AD","floatShares":15563300,"roa":"0.02%","roe":"22.68%","lyrEps":0.555055,"volumeRatio":0.7206132626798357,"shares":86379877,"dividePrice":0,"high":38.36,"amplitude":0.016032,"preClose":38.05,"low":37.75,"week52Low":33.71,"pbRate":"2.60","psRate":"15.42","week52High":60.82,"institutionHeld":0.3358,"latestPrice":38.12,"eps":6.185934,"divideRate":0,"volume":187406,"delay":0,"ttmEps":6.185934,"open":38.29,"prevYearClose":53.62,"prevWeekClose":38.5,"prevMonthClose":36.66,"prevQuarterClose":36.26,"fiveDayClose":38.73,"twentyDayClose":35.7,"sixtyDayClose":39.69,"dividendPayoutRate":40.52599213795753,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0.4274298457535774},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AD\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-07","symbol":"AD","fiscalQuarterEnding":"2026/06","expectedEps":0.27,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786075200000,"reportTimeType":"pre","actualEps":0.44},{"date":"2026-06-11","symbol":"AD","amount":11,"announcedDate":"2026-06-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-11","defaultRemindTime":1781184600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-25","payableDate":"2026-06-11","currency":"USD","dateTimestamp":1781150400000,"payDate":"2026-06-25"},{"market":"US","date":"2026-05-08","symbol":"AD","fiscalQuarterEnding":"2026/03","expectedEps":-0.06,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778212800000,"reportTimeType":"pre","actualEps":0.42},{"market":"US","date":"2026-02-20","symbol":"AD","fiscalQuarterEnding":"2025/12","expectedEps":0.32,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1771563600000,"reportTimeType":"pre","actualEps":0.48},{"date":"2026-01-23","symbol":"AD","amount":10.25,"announcedDate":"2026-01-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-01-23","defaultRemindTime":1769178600000,"name":"Array Digital Infrastructure Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-02-02","payableDate":"2026-01-23","currency":"USD","dateTimestamp":1769144400000,"payDate":"2026-02-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AD\",market:\"US\",,,undefined,":[{"executeDate":"2025-08-20","recordDate":"2025-08-11","paymentDate":"2025-08-19","value":23,"currency":"USD"},{"executeDate":"2026-01-23","recordDate":"2026-01-23","paymentDate":"2026-02-02","value":10.25,"currency":"USD"},{"executeDate":"2026-06-11","recordDate":"2026-06-11","paymentDate":"2026-06-25","value":11,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AD\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.2,"hold":0.6,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.2,"analysts":5,"updateTime":1786420800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AD\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AD","date":"2026-09-11","current":6.162368,"percent":0.3,"low":-273.92211,"twenty":-174.161842,"median":21.222313,"eighty":260.167256,"high":320.844562,"avg":57.30785,"sd":169.935215,"marketCap":3290525950},"quantilePoints":[{"date":"2025-08-15","current":-273.850129,"twenty":-273.893318,"median":-273.850129,"eighty":-273.612593,"marketCap":6572403103},{"date":"2025-08-22","current":-200.933798,"twenty":-273.763753,"median":-273.490226,"eighty":-228.502362,"marketCap":4822411161},{"date":"2025-08-29","current":-194.49692,"twenty":-273.591,"median":-200.933798,"eighty":-194.626488,"marketCap":4667926077},{"date":"2025-09-05","current":-189.890035,"twenty":-273.511821,"median":-195.360711,"eighty":-192.519268,"marketCap":4557360841},{"date":"2025-09-12","current":-184.671298,"twenty":-272.73443,"median":-194.119011,"eighty":-189.199003,"marketCap":4432111159},{"date":"2025-09-19","current":-175.349555,"twenty":-256.070925,"median":-192.368109,"eighty":-183.778715,"marketCap":4208389313},{"date":"2025-09-26","current":-169.950862,"twenty":-200.271577,"median":-189.74607,"eighty":-179.092649,"marketCap":4078820677},{"date":"2025-10-03","current":-180.892213,"twenty":-197.170296,"median":-184.671298,"eighty":-177.638601,"marketCap":4341413113},{"date":"2025-10-10","current":-180.028422,"twenty":-195.252737,"median":-184.059446,"eighty":-177.861746,"marketCap":4320682131},{"date":"2025-10-17","current":-179.200623,"twenty":-194.756057,"median":-183.555568,"eighty":-177.18511,"marketCap":4300814940},{"date":"2025-10-24","current":-177.581015,"twenty":-194.345757,"median":-180.586287,"eighty":-177.242697,"marketCap":4261944349},{"date":"2025-10-31","current":-176.105372,"twenty":-193.617663,"median":-180.892213,"eighty":-177.242697,"marketCap":4226528922},{"date":"2025-11-07","current":-171.642452,"twenty":-192.972746,"median":-180.010426,"eighty":-176.702827,"marketCap":4119418849},{"date":"2025-11-14","current":241.378582,"twenty":-192.09564,"median":-179.920448,"eighty":-175.407141,"marketCap":3917333000},{"date":"2025-11-21","current":240.473745,"twenty":-190.782619,"median":-179.452562,"eighty":-172.916544,"marketCap":3902648400},{"date":"2025-11-28","current":261.764027,"twenty":-189.890035,"median":-179.056658,"eighty":-170.850644,"marketCap":4248168400},{"date":"2025-12-05","current":265.117247,"twenty":-189.602105,"median":-178.588771,"eighty":240.420519,"marketCap":4302587800},{"date":"2025-12-12","current":265.543053,"twenty":-189.098227,"median":-177.958923,"eighty":244.409875,"marketCap":4309498200},{"date":"2025-12-19","current":274.059166,"twenty":-184.671298,"median":-177.329076,"eighty":249.043083,"marketCap":4447706200},{"date":"2025-12-26","current":286.620433,"twenty":-184.613712,"median":-177.149119,"eighty":260.390804,"marketCap":4651563000},{"date":"2026-01-02","current":285.396241,"twenty":-184.556126,"median":-176.681232,"eighty":261.913059,"marketCap":4631695600},{"date":"2026-01-09","current":277.199482,"twenty":-183.965869,"median":-175.78145,"eighty":263.648217,"marketCap":4498670400},{"date":"2026-01-16","current":297.372025,"twenty":-183.569965,"median":-174.161842,"eighty":266.266922,"marketCap":4826050600},{"date":"2026-01-23","current":320.844562,"twenty":-183.555568,"median":-173.981886,"eighty":271.994008,"marketCap":5206986400},{"date":"2026-01-30","current":252.1834,"twenty":-183.238845,"median":-172.02036,"eighty":268.321434,"marketCap":4092684400},{"date":"2026-02-06","current":257.665648,"twenty":-182.648588,"median":-169.950862,"eighty":267.224985,"marketCap":4181655800},{"date":"2026-02-13","current":269.109175,"twenty":-182.115917,"median":238.717297,"eighty":267.224985,"marketCap":4367372800},{"date":"2026-02-20","current":267.938209,"twenty":-181.48247,"median":240.926164,"eighty":268.704659,"marketCap":4348369200},{"date":"2026-02-27","current":255.643071,"twenty":-181.064971,"median":244.409875,"eighty":267.842403,"marketCap":4148831400},{"date":"2026-03-06","current":262.668864,"twenty":-180.769843,"median":247.365175,"eighty":267.342081,"marketCap":4262853000},{"date":"2026-03-13","current":255.643071,"twenty":-180.229973,"median":249.043083,"eighty":266.671437,"marketCap":4148831400},{"date":"2026-03-20","current":82.941723,"twenty":-180.021224,"median":248.376453,"eighty":265.819826,"marketCap":4043906649},{"date":"2026-03-27","current":82.498564,"twenty":-179.985233,"median":245.210832,"eighty":265.628214,"marketCap":4022299967},{"date":"2026-04-02","current":84.413012,"twenty":-179.95644,"median":244.199544,"eighty":265.543053,"marketCap":4115640834},{"date":"2026-04-10","current":87.513828,"twenty":-179.920448,"median":240.447132,"eighty":265.117247,"marketCap":4266824209},{"date":"2026-04-17","current":87.691125,"twenty":-179.920448,"median":236.588268,"eighty":264.265636,"marketCap":4275468504},{"date":"2026-04-24","current":86.627343,"twenty":-179.596527,"median":87.806368,"eighty":264.052733,"marketCap":4223602732},{"date":"2026-05-01","current":88.098909,"twenty":-179.308596,"median":87.655666,"eighty":263.999507,"marketCap":4295350384},{"date":"2026-05-08","current":87.40745,"twenty":-179.200623,"median":87.575882,"eighty":263.414024,"marketCap":4261637632},{"date":"2026-05-15","current":21.135166,"twenty":-178.912692,"median":87.337865,"eighty":263.147896,"marketCap":4402539647},{"date":"2026-05-22","current":21.338509,"twenty":-178.876701,"median":86.919883,"eighty":263.041444,"marketCap":4444896694},{"date":"2026-05-29","current":21.222313,"twenty":-178.646357,"median":86.396857,"eighty":262.74338,"marketCap":4420692667},{"date":"2026-06-05","current":21.55845,"twenty":-178.444805,"median":85.972934,"eighty":262.32822,"marketCap":4490711460},{"date":"2026-06-12","current":16.645033,"twenty":-178.17847,"median":85.475751,"eighty":262.157897,"marketCap":3467226884},{"date":"2026-06-18","current":16.18855,"twenty":-177.926531,"median":85.370237,"eighty":262.136607,"marketCap":3372139635},{"date":"2026-06-26","current":14.893798,"twenty":-177.667394,"median":85.086615,"eighty":261.913059,"marketCap":3102437619},{"date":"2026-07-02","current":15.151088,"twenty":-177.480239,"median":84.907561,"eighty":261.764027,"marketCap":3156032250},{"date":"2026-07-10","current":14.416565,"twenty":-177.285886,"median":83.339562,"eighty":261.593705,"marketCap":3003028221},{"date":"2026-07-17","current":14.495412,"twenty":-177.192309,"median":82.498564,"eighty":261.253061,"marketCap":3019452383},{"date":"2026-07-24","current":14.184174,"twenty":-177.005154,"median":82.259257,"eighty":261.061448,"marketCap":2954620167},{"date":"2026-07-31","current":14.516162,"twenty":-176.767611,"median":81.532476,"eighty":260.944352,"marketCap":3023774530},{"date":"2026-08-07","current":14.794201,"twenty":-176.56606,"median":80.513209,"eighty":260.8379,"marketCap":3081691310},{"date":"2026-08-14","current":5.765224,"twenty":-176.069381,"median":21.824041,"eighty":260.742094,"marketCap":3087300300},{"date":"2026-08-21","current":5.739385,"twenty":-175.867829,"median":21.55845,"eighty":260.635642,"marketCap":3073463660},{"date":"2026-08-28","current":5.731311,"twenty":-175.579899,"median":21.315684,"eighty":260.358869,"marketCap":3069139710},{"date":"2026-09-04","current":6.254541,"twenty":-175.112012,"median":21.259662,"eighty":260.252418,"marketCap":3349331670},{"date":"2026-09-11","current":6.144727,"twenty":-174.161842,"median":21.222313,"eighty":260.167256,"marketCap":3290525950}],"updateTime":1789292345710},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AD\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621673320","title":"Array Digital Infrastructure approves 2026 annual incentive plan with 80% company performance weighting","url":"https://stock-news.laohu8.com/highlight/detail?id=2621673320","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621673320?lang=en_us&edition=fundamental","pubTime":"2026-03-24 20:50","pubTimestamp":1774356635,"startTime":"0","endTime":"0","summary":"Array approved a 2026 Annual Incentive Plan covering all associates, including the President and CEO, while the Chair does not participate.Officer bonuses under the plan are based on two components: company performance weighted at 80% and individual performance weighted at 20%.Company performance is measured using adjusted revenue (40%) and adjusted OIBDA (40%).A third company metric, new cash site rental revenue, carries a 20% weighting.No bonus is due unless an officer remains employed through the payout date, with pro-rated eligibility in cases of retirement or death.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Array Digital Infrastructure Inc. published the original content used to generate this news brief via EDGAR, the Electro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8DQGC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","AD","TDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084991","title":"Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084991","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084991?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:01","pubTimestamp":1774296060,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO and BOSTON, March  23, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential f","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/23/3260824/0/en/Apogee-Therapeutics-Inc-Announces-Proposed-300-Million-Underwritten-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","AD","APGE","BK4132","USA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621703738","title":"Apogee data for zumilokibart in AD ‘a home-run success,’ says Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703738","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703738?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:15","pubTimestamp":1774268157,"startTime":"0","endTime":"0","summary":"Citi analyst Geoff Meacham calls Apogee’s positive 52-week Phase 2a maintenance data for zumilokibart in atopic dermatitis “a home-run success that...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/apogee-data-for-zumilokibart-in-ad-a-home-run-success-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/apogee-data-for-zumilokibart-in-ad-a-home-run-success-says-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621261758","title":"Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2621261758","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621261758?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:05","pubTimestamp":1774022700,"startTime":"0","endTime":"0","summary":"Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March  20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eis","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/20/3259865/0/en/Results-from-Real-World-Long-Term-Treatment-Persistence-with-LEQEMBI-lecanemab-irmb-in-the-United-States-Presented-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UBCP","CDR","BK4132","MCI","AD","LU1169590202.USD","BK4023","PD","BK4080","CSF","LU1169589451.USD","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620775892","title":"AdAlta secures Canadian patent to complete global AD-214 protection","url":"https://stock-news.laohu8.com/highlight/detail?id=2620775892","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620775892?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:09","pubTimestamp":1773961744,"startTime":"0","endTime":"0","summary":"AdAlta Ltd. ( ($AU:1AD) ) has provided an announcement. AdAlta has secured a Canadian composition of matter patent for its first-in-class anti-fibr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/adalta-secures-canadian-patent-to-complete-global-ad-214-protection?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/adalta-secures-canadian-patent-to-complete-global-ad-214-protection?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AD","BK4132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620790242","title":"Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620790242","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620790242?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:00","pubTimestamp":1773950400,"startTime":"0","endTime":"0","summary":"NEWTON, Mass., March  19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics tha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3259413/0/en/Acumen-Pharmaceuticals-to-Report-Fourth-Quarter-and-Year-End-2025-Financial-Results-on-March-26-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABOS","BK4539","BK4132","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620285092","title":"INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2620285092","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620285092?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:00","pubTimestamp":1773921600,"startTime":"0","endTime":"0","summary":"Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March  19, 2026  --  INmune Bio Inc.  , a clinical-stage inflammation and immunology company, today announced that Malú Gámez Tansey, Ph.D., Professor of Neurology at the Stark Neuroscience Research Institute at Indiana University School of Medicine, will feature the Company’s Phase 2 MINDFuL trial of XPro  as a centerpiece of her plenary presentation at AD/PD 2026 — the world’s leading international conference on Alzheimer’s and Parkinson’s diseases — taking place March 17–21, 2026 in Copenhagen, Denmark. Dr. Tansey is among the most respected voices in neuroimmunology, having spent her career mapping the role of peripheral inflammation in neurodegenerative disease and identifying soluble TNF as one of its most consequential drivers. Her plenary talk, titled “The Role of Peripheral Inflammation in Neurode","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/19/3258912/0/en/INmune-Bio-s-MINDFuL-Trial-Featured-at-AD-PD-2026-Plenary-as-Successful-Example-of-How-to-Approach-Clinical-Trials-Targeting-Inflammation-in-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","LU1169590202.USD","BK4132","AD","PD","INMB","BK4139","BK4023"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620825580","title":"Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620825580","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620825580?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:15","pubTimestamp":1773836100,"startTime":"0","endTime":"0","summary":"Additional biomarker analysis reveals higher CSF levels of DOPA decarboxylase (DDC – an emerging PD biomarker) at baseline with a reduction following 90 days of dosing with GT-02287 in individuals wit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258138/0/en/Gain-Therapeutics-Presents-Additional-Clinical-and-Biomarker-Data-from-Phase-1b-Clinical-Study-of-GT-02287-and-Preclinical-Data-from-Novel-Chemical-Series-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4119","BK4212","GANX","GT","LU1169589451.USD","BK4132","BK4585","LU1169590202.USD","DDC","PD","BK4139","BK4588","BK4023","CSF","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620595255","title":"Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2620595255","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620595255?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:55","pubTimestamp":1773831300,"startTime":"0","endTime":"0","summary":"- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March  18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focuse","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/18/3258004/37216/en/Aclaris-Therapeutics-Completes-Enrollment-in-Phase-2-Trial-of-Bosakitug-ATI-045-in-Atopic-Dermatitis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","TSLP","BSA","PD","PK","LU2065731478.USD","ATI","BK4023","BK4007","IE00B19Z4B17.USD","EASI","BK4218","BK4006","LU1169590202.USD","IE00B66KJ199.SGD","AD","IE00B7SZL793.SGD","BK4181","IGA","BK4187","BK4132","LU1878469433.USD","IE0031619046.USD","LU1169589451.USD","ACRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620408109","title":"Longeveron Announces 2025 Full Year Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620408109","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620408109?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:05","pubTimestamp":1773777900,"startTime":"0","endTime":"0","summary":"Stephen Willard, Chief Executive Officer, Longeveron Inc. (LGVN)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257647/0/en/Longeveron-Announces-2025-Full-Year-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","IND","LGVN","BK4588","BK4139","BK4023","BK4575","SAP","BK4528","BK4585","JPO","MSC","AD","BK4613","BK4150"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424058","title":"Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424058","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424058?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:00","pubTimestamp":1773748800,"startTime":"0","endTime":"0","summary":"NEWTON, Mass., March  17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid bet","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257081/0/en/Acumen-Pharmaceuticals-Presents-Studies-on-Enhanced-Brain-Delivery-Biomarker-Research-and-Novel-Antibodies-at-Advances-in-Alzheimer-s-Treatment-at-International-Conference-on-Alzhe.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4187","BK4135","BK4539","BK4139","BBB","BK4588","BK4132","AD","SPR","ABOS","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620429768","title":"Cognition Therapeutics Presents Evidence of Zervimesine’s Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620429768","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620429768?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:30","pubTimestamp":1773747000,"startTime":"0","endTime":"0","summary":"PURCHASE, N.Y., March  17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257029/0/en/Cognition-Therapeutics-Presents-Evidence-of-Zervimesine-s-Impact-on-Neuropsychiatric-Symptoms-of-Dementia-with-Lewy-Bodies-at-AD-PD-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4132","CGTX","LU1169589451.USD","BK4007","LU0205194284.USD","BK4097","LU0240878834.USD","AD","LU0345774391.USD","LU1169590202.USD","LU0205193047.USD","LU0240877869.USD","PD","LU0348723411.USD","LU0345774631.USD","BK4023","DLB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620912425","title":"Maintaining Buy on Acumen (ABOS): EBD-Enabled Alzheimer’s Pipeline, Extended Runway, and Discounted Valuation Ahead of ALTITUDE-AD Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2620912425","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620912425?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:35","pubTimestamp":1773743720,"startTime":"0","endTime":"0","summary":"Bank of America Securities analyst Jason Zemansky has maintained their bullish stance on ABOS stock, giving a Buy rating yesterday. Jason Zemansky ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/maintaining-buy-on-acumen-abos-ebd-enabled-alzheimers-pipeline-extended-runway-and-discounted-valuation-ahead-of-altitude-ad-readout-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/maintaining-buy-on-acumen-abos-ebd-enabled-alzheimers-pipeline-extended-runway-and-discounted-valuation-ahead-of-altitude-ad-readout-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0149725797.USD","LU0130103400.USD","LU0211331839.USD","LU0130517989.USD","LU1506573853.SGD","LU0310800965.SGD","IE00B7SZLL34.SGD","LU1363072403.SGD","LU0203347892.USD","LU0477156797.USD","LU0208291251.USD","IE0001KFT4U8.USD","LU0320765489.SGD","LU0648000940.SGD","ABOS","LU0256863902.USD","LU2129689514.USD","LU2129689605.HKD","LU0640476718.USD","LU0256863811.USD","LU0070302665.USD","IE00BLSP4452.SGD","LU0170899867.USD","BK4588","LU1496350502.SGD","LU1035773651.USD","LU0320765646.SGD","LU0052756011.USD","LU0098860793.USD","BAC","LU1883839398.USD","AD","LU0787776722.HKD","LU1069347547.HKD","BK4539","LU1791807156.HKD","BK4504","LU0648001328.SGD","LU0128525689.USD","IE00BKVL7J92.USD","LU0306807586.USD","IE00BLSP4239.USD","LU1201861249.SGD","BK4559","LU0980610538.SGD","LU0971096721.USD","IE0034235188.USD","LU0106831901.USD","LU1880398554.USD","IE00BBT3K403.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619363454","title":"Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2619363454","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619363454?lang=en_us&edition=fundamental","pubTime":"2026-03-16 18:30","pubTimestamp":1773657000,"startTime":"0","endTime":"0","summary":"Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro, in vivo and non-human primate study results, that support development candidat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256089/0/en/Acumen-Pharmaceuticals-Announces-35-75-Million-Private-Placement-to-Advance-Potential-Best-in-Class-Molecules-from-Amyloid-Beta-Oligomer-Selective-Enhanced-Brain-Delivery-Portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBB","ABOS","BK4139","BK4135","BK4539","BK4132","CNS","AD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":194,"code":"91000000","status":"200"}]}}